Mr. Chen has served as counsel to:
- LionRock Capital in connection with its acquisition of International Sports Capital S.p.A., which holds 31.05% shares in FC Internazionale Milano S.p.A.
- FountainVest Partners in connection with its going private acquisition of Chinese online career platform Zhaopin Limited, together with Hillhouse Capital and SEEK International*
- FountainVest Partners in a number of transactions, including its establishment of a joint venture in China with WME | IMG, a global sports, fashion and entertainment talent management company, together with Sequoia Capital China and Tencent, and its investments in leading China-based businesses, including Meituan-Dianping, Fangdd.com, and Codoon*
- ZQ Capital in its acquisition of Angiotech Pharmaceuticals, Inc., a medical device manufacturer, and its $210 million PIPE investment in NYSE-listed Nu Skin Enterprises*
- Horizons Ventures Limited, the private investment arm of Li Ka-Shing, in its investments in numerous early-stage technology companies based in the U.S. and Canada*
- Co-investment fund formed by Focus Media and FountainVest Partners in connection with investments in the sports, media and entertainment industries*
- TOM Group Limited, in their investments in WeLab Holdings (WeLend) and Rubikloud Technologies Inc.*
- China Media Capital and FountainVest Partners in their investment in the Greater China business of large-screen movie exhibitor IMAX Corp. (awarded “Mid-Cap Deal of the Year” by Asian Venture Capital Journal (2014)) and the sale of their shares in the Hong Kong IPO of IMAX China*
- the buyer group (including the Carlyle Group, FountainVest Partners, and CITIC Capital Partners) in connection with the US$3.7 billion acquisition of Focus Media, China’s then-largest leveraged buy-out (awarded “Global M&A Deal of the Year: China Private Equity” by The American Lawyer (2014) and “Private Equity Deal of the Year” by IFLR (2014) and China Law & Practice (2013))*
- LionRock Capital in connection with numerous transactions*
- Goldman Sachs as financial adviser to the Special Committee of NASDAQ-listed AsiaInfo-Linkage in a US$890 million going-private acquisition led by CITIC Capital Partners*
- Lazard as financial adviser to the buyer group in its going-private acquisition of NASDAQ-listed Yucheng Technologies Limited*
- the private equity buyer consortium in its going-private acquisition of China jewelry retailer and distributor NASDAQ-listed LJ International*
- the Special Committee of NASDAQ-listed CNinsure in connection with a proposed US$950 million going-private transaction involving its chairman and private equity sponsors, including TPG*
- the independent board of NYSE-listed Acorn International, a China-based TV retailer, in connection with its consideration of an unsolicited partial tender offer by its co-founders*
- the founder and controlling shareholder of Tiens Biotech Group in a going-private squeeze-out merger transaction*
- the Special Committee of Board of Directors of NASDAQ-listed Solarfun Power Holdings, a solar cell producer, in connection with its US$370 million sale of a controlling stake to Hanwha Corporation*
- Sequoia Capital, Citic Capital and FountainVest Partners in a US$180 million PIPE investment in NASDAQ-listed SINA Corporation*
- NYSE-listed WuXi Pharmatech, a leading Chinese R&D outsourcing company, in its announced (and subsequently terminated) acquisition by Charles River Laboratories for US$1.6 billion*
- NYSE-listed Mindray Medical International Limited, a China-based medical device company, in its US$202 million acquisition of the worldwide patient monitoring business of Datascope, creating the then-third-largest player in the global patient monitoring industry*
* Denotes experience prior to joining Goodwin.
- 代表莱恩资本收购持有国际米兰足球俱乐部31.05%的股份的International Sports Capital S.p.A.。
- 代表方源资本，处理其联合高瓴资本及SEEK International对中国招聘网站智联招聘进行私有化的交易。*
- 代表方源资本处理多宗交易，包括联合红杉资本和腾讯与全球体育、时尚娱乐经纪公司WME-IMG在中国设立合资公司，以及其对包括美团点评、房多多和咕咚网在内的主要中资企业所进行的投资。*
- 代表倍哲资本处理其收购医疗器械制造商Angiotech Pharmaceuticals的交易，以及其对纽约上市的如新企业（Nu Skin Enterprises）进行的私人投资公开股票(PIPE)交易。*
- 代表李嘉诚旗下的维港投资投资于美国和加拿大的多家早期技术公司。*
- 代表分众传媒与方源资本成立的共同投资基金，处理其在运动、传媒和娱乐行业的投资交易。*
- 代表TOM集团投资于WeLab Holdings（WeLend）和Rubikloud Technologies Inc.。*
- 代表华人文化产业投资基金和方源资本投资于大屏幕电影参展商IMAX Corp.的大中华业务（该交易获得《亚洲创业投资期刊》（2014）评为的“年度最佳中型交易”）以及在IMAX中国的香港首次公开募股中出售持有的股份。*
- 为买方银团（由凯雷、方源资本、中信资本、光大控股、复星国际和公司主席组成）提供咨询服务，协助处理其作价37亿美元收购分众传媒控股有限公司（纳斯达克上市代号：FMCN）的事宜。此私有化交易是中国历来最大型的杠杆收购（该交易获《美国律师》杂志评为2014年度“全球年度最佳中国私募股权并购交易”，并获《全球金融法律评论》杂志和《中国法律商务》杂志分别评为2014年度及2013年度“最佳私募股权交易“。*
- 代表莱恩资本处理其多项交易。*
- 代表亚信联创(纳斯达克上市代号：ASIA) 特别委员会的财务顾问高盛公司，协助其处理由中信资本牵头的财团作价8.9亿美元对亚信联创进行的收购。*
- 为担任买方集团财务顾问的瑞德集团提供咨询服务，协助其处理买方集团收购宇信易诚科技有限公司（纳斯达克上市代号：YTEC）的事宜。*
- 代表私募股权银团，协助其处理私有化于纳斯达克上市的中资珠宝零售商和分销商LJ国际有限公司的事宜。*
- 代表泛华保险服务(纳斯达克上市代号：CISG) 特别委员会，协助处理拟进行并涉及其董事长及私募股权保荐人 (包括德州太平洋集团 (TPG)) 的私有化交易，价值9.5亿美元。*
- 为中资电视营销商橡果国际（纽约上市代号：ATV）独立董事会提供咨询服务，协助该公司处理其考虑是否接受由其共同创办人主动提出的部分收购要约。*
- 代表天狮生化的控股股东处理天狮生化的私有化交易。*
- 代表纳斯达克上市的太阳能电池制造商林洋新能源控股特别委员会，协助其处理向韩华集团作价3.7亿美元出售控股股权的事宜。*
- 为红杉资本、中信资本及方源资本提供咨询服务，协助处理其对新浪公司进行的1.8亿美元投资。*
- 为在纽约上市的中国大型研发外包服务公司药明康德（WuXi Pharmatech）提供咨询服务，协助处理其宣布(及其后遭终止)由 Charles River Laboratories 进行收购的事宜，价值 16 亿美元。*
- 为在纽约上市的中资医疗器械生产商迈瑞医疗国际股份有限公司(Mindray Medical International Limited)提供咨询服务，协助处理其以 2.02 亿美元收购 Datascope 的全球病人监护业务，从而成为全球病人监护行业中第三大企业。*
*代表加入高赢之前办理的交易